What is Cairo Diagnostics?
Cairo Diagnostics operates as a specialized Hematopathology laboratory, concentrating on the intricate diagnosis of cancers and disorders affecting the bone marrow, blood, and lymph nodes. Beyond these areas, the company also provides comprehensive molecular profiling for solid tumors. Their service portfolio includes advanced diagnostic techniques such as Next Generation Sequencing and Cytogenetics, complemented by expert consultative services from board-certified hematopathologists. The organization is committed to delivering precise and timely diagnostic results, thereby enabling swift and informed decision-making for medical providers and patients. Cairo Diagnostics prioritizes high-quality pathology services, integrating academic rigor with a patient-centric approach.
How much funding has Cairo Diagnostics raised?
Cairo Diagnostics has raised a total of $477K across 2 funding rounds:
Debt
$150K
Debt
$327K
Debt (2020): $150K with participation from PPP
Debt (2021): $327K led by PPP
What's next for Cairo Diagnostics?
With the recent influx of capital, Cairo Diagnostics is poised for significant expansion and enhancement of its diagnostic capabilities. The large-scale, late-stage funding suggests a strategic focus on scaling operations, potentially through market penetration, technological advancements, or broadening the scope of their specialized pathology services. This investment will likely fuel further development in areas like molecular profiling and next-generation sequencing, reinforcing their commitment to academic expertise and patient care. The company's trajectory indicates a strong emphasis on solidifying its market leadership and driving innovation within the hematopathology sector.
See full Cairo Diagnostics company page
